There’s little chance that FDA premarket clearance and Centers for Medicare & Medicaid Services coverage with evidence development (CED) decisions will be coordinated in the near future, Louis Jacques, director of CMS’s Coverage & Analysis Group, said June 1 at the Medical Device Manufacturers Association annual conference in Washington, D.C.